Inactivated Streptococcus Salivarius for Glucose Intolerance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for glucose intolerance, particularly in prediabetes and type 2 diabetes, are insufficient and often associated with side effects, necessitating the development of new compounds or compositions that can safely and effectively regulate glucose homeostasis.

Innovation Solution

The use of inactivated bacteria of the genus Streptococcus, specifically Streptococcus salivarius, or their membrane fractions, which contain a gene coding for a 16S ribosomal RNA with a specific nucleotide sequence, to improve glucose intolerance and prevent or treat associated metabolic diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If metformin is used to treat glucose intolerance, then blood glucose level is controlled, but unwanted side effects occur such as nausea, vomiting, diarrhea, abdominal pains, and loss of appetite

Engineering Contradiction:

Improveblood glucose controlVSAvoidunwanted side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces inactivated bacteria as an intermediary substance that mediates the treatment of glucose intolerance. Instead of using metformin directly which causes harmful side effects, the inactivated bacteria serve as a mediator that modulates the gut microbiota and indirectly improves glucose metabolism, thereby achieving blood glucose control without the direct harmful effects of metformin

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent uses inactivated bacteria as a copy or surrogate of live probiotic bacteria. The inactivated form retains the beneficial effects of probiotics on gut microbiota modulation and glucose metabolism while eliminating the risks associated with live bacteria, such as infection in immunocompromised individuals. This copying approach allows safe administration to children and adolescents

Inventive Principle:

Principle #26Copying

2Reliability

If metformin is used for long-term treatment, then blood glucose is controlled, but risk of vitamin B6 and B12 deficiency increases with neurologic complications

Engineering Contradiction:

Improvelong-term blood glucose controlVSAvoidvitamin deficiency and neurologic complications

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The inactivated bacteria act as a long-term intermediary treatment that continuously modulates gut microbiota composition and function. This sustained modulation improves insulin sensitivity and glucose metabolism over the long term without depleting vitamin stores or causing neurologic complications, unlike metformin which requires prolonged use and accumulates harmful effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs inactivated bacteria as a disposable therapeutic agent that can be administered repeatedly without accumulating harmful effects. Each dose of inactivated bacteria provides a fresh modulation of gut microbiota without the cumulative toxicity of long-term metformin use, making it suitable for lifelong prevention and treatment

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If lifestyle adjustments are made to prevent type 2 diabetes, then progression may be prevented, but adjustments are often unrealistic or insufficient

Engineering Contradiction:

Improveprevention of type 2 diabetesVSAvoidlifestyle adjustment feasibility

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The inactivated bacteria serve as a pharmacological intermediary that supplements insufficient lifestyle adjustments. While lifestyle changes remain the foundation of prevention, the inactivated bacteria provide an additional mechanism to modulate gut microbiota and improve glucose metabolism, making prevention more effective when lifestyle adjustments alone are unrealistic or insufficient

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent uses inactivated bacteria as a surrogate for ideal lifestyle conditions. Instead of requiring perfect adherence to diet and exercise regimens, the inactivated bacteria copy the beneficial metabolic effects of a healthy lifestyle by modulating gut microbiota, providing a more feasible alternative for individuals who cannot maintain strict lifestyle adjustments

Inventive Principle:

Principle #26Copying

Data Source

PatentUS20250073283A1Streptococcus for use in the treatment of glucose intolerance

Publication Date: 2025.03.06 INSTITUT NATIONAL DE LA RECHERCHE POUR L AGRICULTURE, L ALIMENTATION ET L ENVIRONNEMENT

AI summary

The present invention relates to an inactivated streptococcus, or a membrane fraction derived therefrom, the streptococcus being obtained from a streptococcus comprising a gene encoding a 16S ribosomal RNA, the gene comprising a nucleotide sequence consisting of the sequence SEQ ID NO: 1, for use in a therapeutic method for preventing and/or treating glucose intolerance and/or a disease associated with glucose intolerance in an individual in need thereof.